The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called “Klotho” inside the body to treat neurodegenerative diseases.
Stage not disclosed · ActiveModality: gene therapy
Aliases AAV9-CMV-sKL
Target Klotho
Partnerships University of Barcelona (exclusive license covering the Company's Klotho pipeline, including KLTO-101)
Status note Named in the primary 10-Q as part of the Company's Klotho pipeline; the University of Barcelona license is planned for use in its clinical development. Modality (AAV gene therapy) per 10-K fallback; stage and indications not stated in the primary excerpts.
KLTO-202
Stage not disclosed · ActiveModality: gene therapy
Aliases AAVmyo-Des-sKL
Target Klotho
Partnerships University of Heidelberg (non-exclusive AAV capsid license); University of Barcelona (exclusive license covering the Company's Klotho pipeline)
Status note The primary 10-Q states the Company plans to use the Heidelberg and Barcelona licenses in upcoming clinical trials of KLTO-202. Modality (AAV gene therapy) per 10-K fallback; stage and indications not stated in the primary excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.